Shandong Pharmaceutical Group (01093.HK) announced in Hong Kong that the nintedanib mesylate inhalation powder developed by the Group has been approved by China’s National Medical Products Administration (NMPA) to conduct clinical trials in China. This product is the first inhalation formulation approved in China for the clinical treatment of pulmonary fibrosis. Nintedanib mesylate is a multi-targeted tyrosine kinase inhibitor capable of slowing the progression of idiopathic pulmonary fibrosis (IPF). The currently marketed formulation is an oral soft capsule.